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patients randomized to aripiprazole completed the study, 
and no serious adverse events were reported. Three patients 
in placebo group discontinued. Aripiprazole was effective 
and generally safe and well-tolerated in the treatment of 
irritability associated with ASD in Japanese children and 
adolescents.
Keywords Aripiprazole · Autism spectrum disorder · 
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Introduction
Before 2013, autistic spectrum disorders (ASD) repre-
sented pervasive developmental disorders of variable sever-
ity, defined as autistic disorder, Asperger’s disorder and 
pervasive developmental disorder—not otherwise speci-
fied (PDD-NOS) in the American Psychiatric Associa-
tion’s Diagnostic and Statistical Manual of Mental Disor-
ders (DSM), Fourth Edition, Text Revision (DSM-IV-TR) 
[1]. The three characteristic manifestations of ASD are 
(1) impaired social interaction, (2) impaired communica-
tion and (3) restricted repetitive and stereotyped patterns 
of behavior, activities, or interests. Diagnostic criteria for 
ASD changed significantly with release of the fifth edi-
tion of the DSM (DSM-5) in 2013 [2]. Autistic disorder, 
Asperger’s disorder and PDD-NOS were collapsed into a 
single diagnosis of ASD—a single diagnosis with consider-
able diagnostic variability. The social and communication 
domains of ASD were combined, leaving two key symptom 
domains: (1) social communication and (2) restricted and 
repetitive behaviors. Understandably, these symptoms can 
have a substantial impact on affected individuals and their 
families. This impact can be further increased by the pres-
ence of associated behaviors such as irritability, which may 
Abstract We evaluated the efficacy and safety of ari-
piprazole in the treatment of irritability in children and ado-
lescents (6–17 years) with autism spectrum disorder (ASD) 
in a randomized, double-blind, placebo-controlled 8-week 
study in Japan. Patients received flexibly dosed aripipra-
zole (1–15  mg/day) or placebo. Ninety-two patients were 
randomized to placebo (n = 45) or aripiprazole (n = 47). 
Aripiprazole produced a significant improvement in the 
mean parent/caregiver-rated Aberrant Behavior Checklist 
Japanese Version irritability subscale score relative to pla-
cebo from week 3 through week 8. Administration of ari-
piprazole provided significantly greater improvement in the 
mean clinician-rated Clinical Global Impression-Improve-
ment scores than placebo from week 2 through week 8. All 
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manifest as tantrums, aggressiveness, self-injurious behav-
ior, and sudden mood changes, all of which can have a sig-
nificant impact on education and social development [3].
Although there are no approved pharmacologic treat-
ments that target the core deficits of ASD, associated 
comorbid symptoms such as irritability may be amelio-
rated by a combination of behavioral and pharmacologic 
approaches, including the use of atypical antipsychotics 
[4]. Risperidone and aripiprazole are approved by the US 
Food and Drug Administration for the treatment of pediat-
ric patients with irritability associated with ASD.
Aripiprazole is an atypical antipsychotic with a partial 
agonism at dopamine D2 receptors and serotonin 5-HT1A 
receptors and an antagonism at 5-HT2A receptors [5, 6]. 
Aripiprazole may have a more favorable side-effect profile 
than other antipsychotics in child and adolescent patients 
with mental health disorder [7], because of its unique 
mechanism of action. Aripiprazole was shown to be effica-
cious while generally safe and well tolerated for the treat-
ment of children and adolescents (ages 6–17  years) with 
irritability associated with ASD in two 8-week, double-
blind, randomized, placebo-controlled studies and in a 
52-week open-label flexible-dose study in the United States 
[8–12].
To our knowledge, no controlled studies have tested 
aripiprazole for use in ASD in Asia including Japan. The 
results of the US study conducted predominantly in Cau-
casian patients may not be generalizable to Japanese chil-
dren with ASD. As genetic/physiologic variation can result 
in differences in metabolism of antipsychotic medications, 
response to treatment and adverse-event risk. Behaviors 
associated with autistic traits were reported to a greater 
extent in the Eastern cultures than the Western culture [13]. 
It is important to study new treatment options in specific 
populations and/or different cultures and environments 
from the viewpoint of the possible existence of ethnic 
differences.
Before 2016, in Japan, the typical antipsychotic pimoz-
ide was the only approved medication for the treatment of 
pediatric patients with irritability associated with ASD. A 
phase 3 clinical study of aripiprazole in Japan was needed 
to obtain approval for this indication from Pharmaceuticals 
and Medical Devices Agency. We conducted a multicenter, 
randomized, double-blind, placebo-controlled, 8-week 
phase 3 study to confirm the efficacy and safety profiles of 
flexibly dosed aripiprazole (1–15 mg/day) in children and 
adolescents with irritability associated with ASD in Japan.
Methods
This multicenter, randomized, double-blind, placebo-
controlled phase 3 study was conducted at 50 sites in 
Japan between June 2012 and June 2015 in accordance 
with ethical principles originating from the Declara-
tion of Helsinki and in compliance with International 
Conference on Harmonization Good Clinical Practice 
guideline. The institutional review board at each site 
approved the protocol. All parents/guardians provided 
written informed consent to participate in the study, and 
patients provided written informed assent when possible. 
The study was registered at ClinicalTrials.gov (identifier: 
NCT01617447).
Subjects
Eligible patients were children and adolescents aged 
6–17 years with a diagnosis of autistic disorder (not ASD) 
defined by the DSM-IV-TR criteria, and with behavio-
ral problems such as irritability, agitation, self-injurious 
behavior, or a combination of these symptoms, and with a 
Clinical Global Impression-Severity of Illness scale (CGI-
S) score of ≥4 and an Aberrant Behavior Checklist Japa-
nese Version (ABC-J) score [14] of ≥18 at screening and 
baseline. The pervasive developmental disorders autism 
society Japan rating scale (PARS) [15] was used as an 
assessment of autistic disorder, not ASD. The validity and 
reliability of ABC-J are equivalent to the original ABC [16] 
and it is useful for assessing behavior problems in Japanese 
patients with intellectual disability [14].
Patients who had complications or histories of schizo-
phrenia, other psychosis, and mood disorders including 
bipolar disorder and major depression according to the 
DSM-IV-TR criteria were excluded. Patients were diag-
nosed by the investigator. Other exclusion criteria included 
a diagnosis of Rett disorder, childhood disintegrative dis-
order, Asperger’s disorder, or pervasive development disor-
der not otherwise specified according to the DSM-IV-TR, 
or a diagnosis of fragile X syndrome. Other exclusion cri-
teria included treatment resistance to antipsychotic medi-
cation, significant risk of committing suicide, or a pro-
found intellectual disability. Patients who had previously 
used aripiprazole, who received any investigational drug 
within 30 days before providing informed consent, or who 
received any concomitant drug or therapy specified as pro-
hibited in the study protocol from the designated time point 
onward were also excluded.
Presence or absence of intellectual disability was diag-
nosed based on the DSM-IV-TR. If intellectual disability 
was diagnosed, the severity was classified into the three 
categories: mild intellectual disability [intelligence quotient 
(IQ) level: 50–55 to approximately 70], moderate intellec-
tual disability (IQ level: 35–40 to 50–55), severe intellec-
tual disability (IQ level: 20–25 to 35–40). IQ was measured 
by one of the standardized methods.
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Study Design
This study consisted of a 4-week screening phase and an 
8-week treatment phase. Patients attended a screening 
visit and a baseline visit. Subsequently, study visits were 
designed at weeks 1, 2, 3, 4, 5, 6, and 8 or at the time of 
early discontinuation. The screening examination was 
conducted during the screening phase to confirm the eli-
gibility of each patient. Patients who met inclusion crite-
ria at baseline were randomized to receive aripiprazole 
or placebo (1:1). Clinicians were required to input infor-
mation regarding eligible patients on the Interactive Web 
Response System (IWRS), and then the registration center 
assigned a trial drug code to each patient. The investigators 
and subjects were blinded to the trial drug randomization 
code. Aripiprazole was initiated at 1 mg/day, with a target 
dosage of 1, 3, 6, 9, 12, or 15  mg/day. The current dose 
was up-titrated in one week intervals to the next higher 
dose according to the patient’s tolerability when the Clini-
cal Global Impressions-Improvement (CGI-I) score was 
assessed as ≥3. The dose was fixed at week 6 and main-
tained until week 8. The dose could be down-titrated any 
time at the clinician’s discretion according to tolerability 
at the current dose. Subsequent up-titration was permitted, 
but patients who experienced a second down-titration were 
excluded from the trial. A final examination was conducted 
at week 8, at the time of treatment completion. If patients 
prematurely discontinued the trial for any reason, the same 
examination was conducted at the time of discontinuation.
Concomitant medications such as antipsychotics, psy-
chostimulants, mood stabilizers, antidepressants, antiepi-
leptics, hypnotics and anxiolytics were prohibited during 
the trial. Patients were allowed to receive ultrashort-acting 
non-benzodiazepine hypnotic agents (i.e. zopiclone, zolpi-
dem and triclofos sodium) as well as the melatonin receptor 
agonist ramelteon at the clinician’s discretion. Anticholin-
ergic antiparkinson drugs (i.e. biperiden and trihexyphe-
nidyl) were permitted for the treatment of extrapyramidal 
symptoms (EPS).
Assessments
Efficacy and safety assessments were performed at each 
study visit, and, when applicable, at the time of early termi-
nation. The primary endpoint was the mean change in the 
caregiver-rated ABC-J irritability subscale score [14] from 
baseline to week 8. The ABC-J irritability subscale is con-
sist of 15 items that include such as “injures self”, “physi-
cal violence to self”, “aggressive to other children and 
adults”, “irritable,” “temper outbursts”, “depressed mood”, 
“mood change”, and “yells” or “screams” etc. Individual 
items are rated from 0 (never a problem) to 3 (severe prob-
lem). The secondary endpoints included the clinician-rated 
mean CGI-I score, the response rate (≥25% reduction from 
baseline in the ABC-J irritability subscale score and a 
CGI-I score of 1 or 2), the mean change in the other ABC-J 
subscale scores (lethargy/social withdrawal (16 items), ste-
reotypy (7 items), hyperactivity (16 items), and inappropri-
ate speech (4 items) from 0 to 3) and the response rate of 
ABC-J score (ABC-J response rate: ≥50% reduction from 
baseline in at least 2 subscales and <10% increase from 
baseline in the remaining subscales) from baseline to week 
8. The CGI-I scale quantifies the clinician’s impression of 
the patient’s improvement or worsening relative to base-
line, scoring from one (very much improved) to seven (very 
much worse).
Additional secondary endpoints included the mean 
changes in the CGI-S score, the Children’s Yale-Brown 
Obsessive–Compulsive Scale (CY-BOCS, compulsion 
scale only) score [17], and the Children’s Global Assess-
ment Scale (CGAS) score [18] from baseline to week 8. 
The CGI-S scale quantifies the clinician’s impression of 
the patient’s current illness severity on a scale from one 
(normal, not at all ill) to seven (among the most extremely 
ill patients). The CY-BOCS is a semi-structured measure 
of obsessive–compulsive symptom severity in children 
and adolescents. Investigators selected compulsive behav-
iors of patients and scored the severities of these behav-
iors with time during the behavior, interference due to the 
behavior, distress associated with the behavior, resistance 
against compulsions and degree of control over compulsive 
thoughts, from 0 (none) to 4 (extreme). CGAS is 100-point 
rating scale measuring psychological, social and school 
functioning for children aged 6–17. Increase in scores of 
CGAS reflects improvement in symptoms. The CY-BOCS 
and CGAS scores were measured at baseline and at weeks 
4 and 8.
Safety assessment measures, which included adverse 
event (AEs) data, vital signs, body weight, and Columbia 
Suicide Severity Rating Scale (C-SSRS), were collected at 
each visit. In addition, the presence and the severity of EPS 
were assessed at each visit by the investigator using the 
Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS), 
the Abnormal Involuntary Movement Scale (AIMS) and 
the Barnes Akathisia Rating Scale (BAS). A12-lead ECG 
and laboratory tests were performed at baseline and at the 
end of treatment.
Statistical Analysis
The randomized sample included all subjects who were 
randomized to double-blind treatment. The safety sam-
ple included all randomized subjects who took at least 
one dose of study medication during the double-blind 
treatment phase, and the efficacy sample included all 
subjects in the safety sample who had at least one 
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post-randomization efficacy evaluation and corre-
sponding baseline value. For continuous measurement, 
change scores were evaluated by analysis of covariance 
(ANCOVA). The ANCOVA models for last observation 
carried forward (LOCF) data sets included the base-
line measure as a covariate and baseline body weight 
(≥40  kg or <40  kg), and treatment as a priori main 
effects. P values that were generated from the ANOVA 
model tested the least square means treatment differ-
ences (TDs). For the treatment response rate and the 
ABC-J response rate, the statistical comparison between 
groups was conducted using Pearson’s chi square analy-
sis. The proportion of the response rate of aripiprazole 
to that of placebo and the two-sided 95% confidence 
interval (CI) were calculated.
All statistical analyses were performed using the 
SAS software (version 9.2; SAS Institute Inc.). For the 
evaluation of efficacy, data values were fundamentally 
expressed as mean (standard error: SE), and statistical 
analysis results were represented as P value and 95% CI. 
Statistical differences were considered significant when 
P < 0.05 (two-sided). Evaluations of prolactin concentra-
tions, weight and body mass index (BMI) changes from 
baseline to week 8 were performed using observed case 
(OC) data set.
Considering alpha = 0.05, beta = 0.15, and seven score 
difference between the aripiprazole and the placebo 
groups on the mean changes of irritability subscale from 
ABC-J, the required sample size was estimated as a min-
imum of 32 patients in each group.
Results
Subject Disposition and Demographics
In total, 99 patients were enrolled and 92 patients were ran-
domly assigned to receive placebo (n = 45) or aripiprazole 
(n = 47). Forty-two (93.3%) patients in the placebo group 
and 47 (100%) patients in the aripiprazole group completed 
the trial; subject disposition is shown in Fig.  1. All rand-
omized patients (n = 92) were included the efficacy and 
safety sample.
The demographic and clinical characteristics at base-
line are shown in Table 1. The mean age of the randomized 
patients was 10.1  years old, and the majority of patients 
were males and younger than 13 years. Fifty-eight (63.0%) 
patients with intellectual disability were included in the 
trial.
Study Medication
The mean daily dose of aripiprazole for the whole 
treatment was 5.7 ± 2.7  mg (±SD). It ranged from 
8.1 to 8.4  mg after day 43, at which time the dose was 
fixed for each patient, with a mean (±SD) daily dose 
of 8.2 ± 4.9  mg at endpoint. The last dose of aripipra-
zole (n = 47) was distributed as follows: 1  mg/day, 
n = 2 (4.3%); 3  mg/day, n = 13 (27.7%); 6  mg/day, n = 8 
(17.0%); 9  mg/day, n = 9 (19.1%); 12  mg/day, n = 3 
(6.4%); and 15  mg/day, n = 12 (25.5%) (Fig.  2). The 
mean daily dose of placebo corresponding to aripipra-
zole was 8.1 ± 2.0 mg (±SD) during the treatment phase. 
The mean (± SD) daily dose of placebo at endpoint was 
Fig. 1  Subject disposition
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12.8 ± 3.6  mg and the prescription pattern of the last 
dose of placebo corresponding to aripiprazole (n = 45) 
was distributed as follows: 1 mg/day, n = 1 (2.2%); 3 mg/
day, n = 1 (2.2%); 6 mg/day, n = 2 (4.4%); 9 mg/day, n = 7 
(15.6%); 12 mg/day, n = 5 (11.1%); and 15 mg/day, n = 29 
(64.4%) (Fig. 2).
Hypnotic/sedative/anxiolytic agents [placebo n = 0 
(0%); aripiprazole n = 2 (4.3%)] were used concomitantly 
during the study. Antiparkinson agents were not used by 
any enrolled patients during the study period.
Efficacy Outcomes
Table 2 shows the results for primary and secondary end-
points. At week 8, the least square mean decrease from 
baseline in the parent/caregiver-rated ABC-J irritability 
subscale score was significantly greater for patients who 
received aripiprazole (Table 2; Fig. 3). The TD was −3.94 
showing statistical significance (Table 2). Significant TDs 
in favor of aripiprazole were detected from week 3 through 
week 8 (Fig.  3). At week 8, aripiprazole group showed a 
statistically significant improvement in mean clinician-
rated CGI-I scores greater than the placebo group [2.7 
(0.1) vs 3.4 (0.1); TD: −0.62 (95% CI: −1.02 to − 0.22); 
p = 0.003]. Significant TDs in favor of aripiprazole were 
observed from week 2 through week 8 (Fig. 4). Response 
rates were significantly greater for patients who received 
aripiprazole from week 3 through week 8 (Table 2; Fig. 5). 
Patients who received aripiprazole demonstrated significant 
improvement versus placebo on the mean ABC-J hyper-
activity subscale score. Subjects treated with aripipra-
zole demonstrated statistically significant improvement 
compared to placebo in the mean CGI-S score from week 
2 through week 8 and the CGAS score at weeks 4 and 8. 
Table 1  Baseline 
demographics and clinical 
characteristics
Data are expressed as number (%) 
a Mean (standard deviation)
b Intellectual disability was diagnosed based on DSM-IV-TR
c Mild (IQ level: 50–55 to approximately 70), moderate (IQ level: 35–40 to 50–55), severe (IQ level: 20–25 
to 35–40)
Placebo (n = 45) Aripiprazole (n = 47) Total (n = 92)
Gender
 Male 36 (80.0) 39 (83.0) 75 (81.5)
 Female 9 (20.0) 8 (17.0) 17 (18.5)
Age, yearsa 9.9 (3.1) 10.3 (3.3) 10.1 (3.2)
 6–12 years 36 (80.0) 33 (70.2) 69 (75.0)
 13–17 years 9 (20.0) 14 (29.8) 23 (25.0)
Height, cma 137.6 (18.1) 140.7 (19.0) 139.2 (18.5)
Weight, kga 36.4 (15.5) 39.1 (17.6) 37.8 (16.5)
 <40 kg 31 (68.9) 26 (55.3) 57 (62.0)
 ≥40 kg 14 (31.1) 21 (44.7) 35 (38.0)
Body mass index, kg/m2a 18.4 (3.8) 18.7 (4.2) 18.6 (4.0)
Intellectual disabilityb 29 (64.4) 29 (61.7) 58 (63.0)
Intelligence quotient (IQ)c
 Mild 16 (35.6) 16 (34.0) 32 (34.8)
 Moderate 7 (15.6) 7 (14.9) 14 (15.2)
 Severe 6 (13.3) 6 (12.8) 12 (13.0)
ABC-J irritability subscale scorea 26.8 (6.5) 27.1 (7.2) 27.0 (6.9)
CGI-Sa 5.0 (0.8) 4.9 (0.7) 4.9 (0.8)




























Fig. 2  Patient distribution of the last doses of aripiprazole and pla-
cebo corresponding to aripiprazole
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There was no significant difference between aripiprazole group and the placebo group in the mean ABC-J stereotypy, 
Table 2  Result of efficacy endpoints (Week 8 LOCF, Efficacy sample)
Data are expressed as least squares mean (standard error). Response rate is defined as ≥25% reduction from baseline in the ABC-J irritability 
subscale score and a CGI-I score of 1 or 2. ABC-J response rate is defined as ≥50% reduction from baseline in at least 2 subscales and <10% 
increase from baseline in the remaining subscales
CY-BOCS Children’s yale-brown obsessive–compulsive scale
a Number of patients (%)
b Difference between aripiprazole and placebo
c Ratio between aripiprazole and placebo
Placebo (n = 45) Aripiprazole (n = 47) Difference or ratio (95% 
confidence interval) P 
valueMean baseline Mean change 
from baseline
Mean baseline Mean change 
from baseline
ABC-J irritability subscale 26.1 (1.0) −7.5 (1.4) 26.9 (1.0) −11.4 (1.3) −3.94 (−7.77, −0.12)b
0.044
Response rate 9 (20.0)a 19 (40.4)a 2.02 (1.02, 3.99)c
0.033
ABC-J hyperactivity subscale 26.8 (1.6) −5.5 (1.5) 29.6 (1.5) −13.0 (1.4) −7.55 (−11.53, −3.57)b
<0.001
ABC-J stereotypy subscale 7.7 (1.0) −2.6 (0.6) 8.2 (1.0) −3.3 (0.6) −0.67 (−2.42, 1.08)b
0.450
ABC-J inappropriate speech subscale 7.3 (0.6) −1.5 (0.4) 7.6 (0.5) −2.2 (0.4) −0.77 (−1.94, 0.41)b
0.197
ABC-J lethargy/social withdrawal subscale 14.8 (1.4) −4.7 (1.1) 15.0 (1.4) −5.2 (1.0) −0.44 (−3.40, 2.51)b
0.768
ABC-J response rate 12 (26.7)a 20 (42.6)a 1.60 (0.89, 2.87)c
0.110
CGI-S 5.0 (0.1) −0.7 (0.2) 4.9 (0.1) −1.4 (0.1) −0.62 (−1.03, −0.21)b
0.003
CY-BOCS (compulsion scale only) 5.4 (0.9) −1.3 (0.5) 6.3 (0.9) −2.0 (0.5) −0.69 (−2.03, 0.66)b
0.311
CGAS 42.3 (2.3) 4.5 (1.4) 42.9 (2.2) 9.8 (1.3) 5.25 (1.53, 8.96)b
0.006
Fig. 3  Mean change from baseline in ABC-J Irritability score by 
week (LOCF; efficacy sample). Data are expressed as least squares 
mean (standard error). ABC-J Aberrant Behavior Checklist Japa-
nese Version, LOCF last observation carried forward. *P < 0.05; 
**P < 0.01 versus placebo
Fig. 4  Mean CGI-I score by week (LOCF; efficacy sample). Data 
are expressed as least squares mean (standard error). CGI-I clinical 
global impressions-improvement score, LOCF last observation car-
ried forward. **P < 0.01; ***P < 0.001 versus placebo
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inappropriate speech and lethargy/social withdrawal sub-
scale scores, as well as ABC-J response rate, CY-BOCS 
(compulsion scale) (Table 2).
Safety Outcomes
During the study, 33 (73.3%) patients in the placebo group 
and 39 (83.0%) patients in the aripiprazole group experi-
enced at least one AE. AEs that occurred at an incidence 
≥5% in any treatment group are shown in Table 3. All AEs 
were mild to moderate in severity in both treatment groups. 
No deaths were reported. Discontinuation due to AEs 
(exacerbation of the ASD) occurred in 1 (2.2%) patient in 
the placebo group. A serious AE (heat disorder) occurred 
in 1 (2.2%) patient in the placebo group. No serious adverse 
events were reported in the aripiprazole group, in which all 
patients completed the study.
EPS-related AEs were found in 1 (2.2%) patient in the 
placebo group and in 3 (6.4%) patients in the aripiprazole 
group. In the aripiprazole group, EPS-related AEs were 
observed in 2 (4.3%) patients (salivary hypersecretion) or 
1 (2.1%) patient each (akathisia, gait disturbance, bradykin-
esia, lisp and tremor). One patient in the aripiprazole group 
experienced salivary hypersecretion, gait disturbance, brad-
ykinesia, lisp and tremor. One (2.2%) patient in the placebo 
group experienced salivary hypersecretion as EPS. The 
severity of all observed EPS-related AEs were considered 
mild in both groups. Mean serum prolactin concentrations 
at baseline were 16.7 ng/mL for placebo and 14.3 ng/mL 
for aripiprazole. Aripiprazole was associated with a signifi-
cant decrease in serum prolactin concentrations compared 
with placebo from baseline to week 8 (−13.8 vs −2.0 ng/
mL; p < 0.001). No patient in the aripiprazole group experi-
enced increase in serum prolactin concentrations. Sedation 
was reported as an AE in 2.1% (n = 1) of the aripiprazole 
group and no patients in the placebo group. Increased appe-
tite was reported as an AE in 4.3% (n = 2) of the aripipra-
zole group and 2.2% (n = 1) in the placebo group. Weight 
gain was reported as an AE in 2.2% (n = 1) of the placebo 
group and no patients in the aripiprazole group.
An increase in body weight of ≥7% from baseline was 
seen in 6.7% of the placebo group and 27.7% of the ari-
piprazole group. However, the mean change in weight from 
baseline to week 8 was not significantly different between 
aripiprazole and placebo (1.24 vs 0.58 kg; p = 0.085). The 
mean change in BMI from baseline to week 8 was signifi-
cantly different between aripiprazole and placebo (0.40 ver-
sus 0.03  kg/m2; p = 0.035). After treatment, the incidence 
rates of total cholesterol ≥200 mg/dL were: placebo, 9.1% 
and aripiprazole, 17.0%. No patients experienced fasting 
blood glucose ≥115  mg/dL, non-fasting blood glucose 
≥200 mg/dL, fasting triglyceride ≥200 mg/dL, non-fasting 
triglyceride ≥500  mg/dL. No marked abnormalities were 
observed in the other clinical laboratory tests along with 
vital sign assessments and the 12-lead ECG, except for 
the decrease in serum prolactin concentrations in the ari-
piprazole group as described above. There were no adverse 
events regarding treatment-related suicidal ideation and 
behavior during the treatment phase.
Discussion
This 8-week, randomized, multicenter, double-blind, pla-
cebo-controlled study demonstrates that flexible-dose ari-
piprazole can be effective in reducing irritability in Japa-
nese children and adolescents with ASD who manifest a 
varying range of irritability including tantrums, aggression, 
Fig. 5  Treatment response rate by week (LOCF; efficacy sample). 
The treatment response was defined as ≥25% reduction from baseline 
in the Aberrant Behavior Checklist Japanese Version Irritability sub-
scale score and a Clinical Global Impressions-Improvement score of 
1 or 2. LOCF last observation carried forward. *P < 0.05; **P < 0.01 
versus placebo
Table 3  Treatment-Emergent Adverse Events that occurred in ≥5% 
of patients in any group
Data are expressed as number (%)
Placebo (n = 45) Aripiprazole (n = 47)
Adverse event 33 (73.3) 39 (83.0)
Somnolence 4 (8.9) 24 (51.1)
Nasopharyngitis 11 (24.4) 10 (21.3)
Decreased appetite 1 (2.2) 6 (12.8)
Nausea 1 (2.2) 3 (6.4)
Vomiting 0 (0.0) 3 (6.4)
Fatigue 0 (0.0) 3 (6.4)
Gastroenteritis 4 (8.9) 1 (2.1)
Bruise 3 (6.7) 1 (2.1)
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and self-injurious behavior. In this study, aripiprazole was 
significantly more efficacious than placebo at treating irri-
tability, as measured on the caregiver-rated ABC-J irritabil-
ity subscale from week 3 through week 8. Aripiprazole also 
produced significant improvements over placebo on the key 
secondary efficacy measure, the clinician-rated CGI-I score 
from week 2 through week 8. In addition, there were sig-
nificantly more responders in the aripiprazole group than in 
the placebo group. The statistically significant reduction in 
irritability symptoms (as measured by the ABC-J irritabil-
ity subscale) is also accompanied by clinically significant 
results (as measured by the CGI-I). No serious adverse 
event was reported in the aripiprazole group, in which all 
patients completed the study. These results showed that 
aripiprazole was effective, generally safe and well-toler-
ated in the treatment of irritability associated with ASD in 
Japanese children and adolescents. Although this study was 
conducted to clarify new treatment options in specific pop-
ulations considering influence of genetic/physiologic varia-
tion and/or cultural and environmental difference on treat-
ment response of aripiprazole, as a consequence, the results 
were consistent with those from previous studies done in 
the US, which showed that aripiprazole is an effective treat-
ment for controlling irritability associated with ASD [8, 9]. 
With antipsychotic medications, children and adolescents 
seem to have a higher risk than adults for experiencing 
adverse events such as EPS, prolactin elevation, sedation, 
weight gain, and metabolic effects [19]. In our study, the 
incidence rates of EPS, prolactin elevation, sedation and 
weight gain in the aripiprazole group were low and the 
incidence rates of clinically significant changes in triglyc-
eride and blood glucose in the aripiprazole group were low. 
The efficacy and safety profile of aripiprazole suggested 
additional benefits of aripiprazole in the pediatric popula-
tion. Nevertheless, it should be noted that ABC-J does not 
fully capture the core symptom domains seen in ASD. Ari-
piprazole also produced greater improvement than placebo 
in the measure of general functioning at weeks 4 and 8, as 
measured on the CGAS score. Improvement of psychologi-
cal, social and school functioning is a meaningful therapeu-
tic goal as the course of treatment of ASD. Therefore, this 
improvement by aripiprazole may have a substantial impact 
on the individuals and their families.
In our results, aripiprazole produced greater improve-
ment in the ABC-J irritability subscale than placebo by 
week 3, when all of the subjects in the aripiprazole group 
were administered 1–6 mg/day of the medication. Marcus 
et al. [8] report that aripiprazole produced greater improve-
ment than placebo by the second week of treatment when 
pediatric patients (aged 6–17  years) received aripiprazole 
5 mg/day. Owen et al. [9] reported similar results as early as 
the first week of treatment, with pediatric patients receiv-
ing aripiprazole 2 mg/day. Those studies, conducted in the 
US [8, 9] suggest an early improvement with low dose ari-
piprazole and corroborate our results. In previous studies, 
patients who received aripiprazole and risperidone demon-
strated significant improvement versus placebo in ABC ste-
reotypy and inappropriate speech subscale scores [8, 9, 20]. 
In the previous fixed-dose study of aripiprazole, aripipra-
zole 15  mg/day demonstrated significant improvements 
more than the placebo group in ABC inappropriate speech 
subscale scores and the CY-BOCS compulsion scale score 
[8]. However, there were no significant differences between 
aripiprazole lower dose (5 mg/day and 10 mg/day) groups 
and placebo group [8]. In our study, there was no signifi-
cant difference between aripiprazole group and placebo 
group in these measures. The proportion of subjects whose 
last dose of aripiprazole was 15 mg/day, the highest dose in 
this study, was only 25.5%. This may explain that the sub-
ject proportion receiving the highest dose of aripiprazole 
was not sufficient to exert a significant improvement in the 
averages of ABC stereotypy and inappropriate speech sub-
scale scores and the CY-BOCS compulsion scale score, as 
compared with the placebo group.
Based on our results and previous randomized controlled 
trials [7], aripiprazole is considered to be well tolerated in 
children and adolescents in Japan and the US. In our study, 
somnolence was the most commonly reported AE in the 
aripiprazole group, and the frequency was higher than that 
in previous US studies [8, 9]. It is unclear why reported rate 
of somnolence was higher in Japanese patients than that 
observed in patients in the US studies, however, this is usu-
ally a well-tolerable AE for patients. Aripiprazole treatment 
was associated with a greater weight gain compared to 
placebo. The average of body weight gain in the aripipra-
zole group was greater than the placebo group, 1.24 and 
0.58  kg, however it was not statistically significant. This 
tendency is similar in previous reports [8, 9]. Mean weight 
gain in aripiprazole group in our study was slightly lower 
than that in previous fixed-dose aripiprazole study (OC: ari-
piprazole 5 mg/day 1.5 kg, aripiprazole 10 mg/day 1.4 kg, 
aripiprazole 15  mg/day 1.6  kg) [8]. The mean change in 
BMI (kg/m2) in aripiprazole group in our study was 0.40 
and slightly lower than that in previous fixed-dose aripipra-
zole study (OC: aripiprazole 5  mg/day 0.5, aripiprazole 
10 mg/day 0.5, and aripiprazole 15 mg/day 0.7) [8]. Weight 
gain was not reported as an AE in the aripiprazole group 
in our study. It was reported in the previous fixed-dose ari-
piprazole study (aripiprazole 5  mg/day 7.7%, aripiprazole 
10 mg/day 1.7%, and aripiprazole 15 mg/day 3.7%) [8]. In 
these studies, no subjects discontinued because of weight 
gain. In previous risperidone study, risperidone therapy was 
associated with an average weight gain of 2.7 kg [20]. The 
weight gain in the risperidone group was associated with 
a mild increase in appetite (49%) or moderate increase in 
appetite (24%) [20]. The lower incidence rate of increased 
Child Psychiatry Hum Dev 
1 3
appetite in aripiprazole group in our study may explain the 
lower average weight gain. In our study, the frequency of 
increased appetite was lower than that in previous US stud-
ies [8, 9]. However, weight gain and BMI increase were 
observed with aripiprazole treatment in Japanese children 
and adolescents ASD patients as well as in US patients [8, 
9]; clinicians who treat children and adolescents with ari-
piprazole should be aware of the potential for weight gain 
and monitor weight change and provide appropriate advice 
when necessary [21]. EPS-related AEs are commonly 
reported for aripiprazole and three (6.4%) patients in the 
aripiprazole group experienced EPS-related AEs in this 
trial, with mild severity. The incidence of EPS-related AEs 
in our study is lower than in previous studies [8, 9]. This 
could possibly be due to the lower starting dose of 1 mg/
day and subsequent dose of 3 mg/day, as compared to pre-
vious studies which started at a higher dose of 2 mg/day, 
followed by 5 mg/day [8, 9].
The decrease in serum prolactin concentrations detected 
in aripiprazole treated patients in our trial has been previ-
ously reported [8, 9], although its clinical consequences 
are unknown [22]. It is known that serum prolactin level 
decrease can be induced by the dopamine D2 receptor par-
tial agonism, a major property of aripiprazole [5, 22].
The findings of this study are strengthened by the use 
of both a parent/caregiver-based rating (ABC irritability 
subscale) and a clinician-based rating (CGI-I scale), both 
of which demonstrated consistent improvements. Aripipra-
zole was generally well tolerated, and completion rate was 
100%. The incidence of discontinuation from study treat-
ment as a result of AEs in our study is lower than that in the 
previous flexible-dose study, in which the study duration 
and the maximum dose of aripiprazole were same as in our 
study [9]. This could possibly be due to the lower starting 
and subsequent dose as compared to that of the previous 
study. These results suggest that this study’s titration strat-
egy provides an appropriate treatment approach for the use 
of aripiprazole in this population.
Aripiprazole and risperidone are the only the US-FDA 
approved medications for treating irritability in ASD, 
however there are few head-to-head data comparing these 
agents [23]. The choice between these two medications 
(dopamine D2 receptor partial agonist versus antagonist) 
should be on the basis of clinical equipoise considering the 
patient’s preference and clinical profile.
To our knowledge, this is the first large, randomised, 
placebo-controlled trial to be conducted to evaluate the 
benefits of aripiprazole for the treatment of Japanese ASD 
patients. Thus, these findings of the study have impor-
tant implications for the treatment of ASD in this popula-
tion. However, there are several limitations to this study. 
The relatively short study duration limits conclusions as 
to the longer-term efficacy or safety in this population in 
Japan, and additional evaluation of the effects of aripipra-
zole on metabolic parameters is warranted. Following this 
short-term study, a long-term study is ongoing to verify 
the efficacy and safety of aripiprazole at flexible doses in 
treating children and adolescents with irritability associ-
ated with ASD in Japan. The flexible-dosing paradigm can-
not accurately identify a minimally effective dosage or a 
maximally tolerated dosage, which should be subjects for 
another study. In the present study, identification of poten-
tial marker of aripiprazole treatment response was not 
included, which should be investigated in a future research.
Summary
We evaluated the short-term efficacy and safety of ari-
piprazole in the treatment of irritability in children and 
adolescents (6–17  years) with ASD in Japan. Ninety-two 
patients were randomized to receive either placebo (n = 45) 
or 1–15 mg/day aripiprazole (n = 47) for 8 weeks. The pri-
mary outcome measure was change in ABC-J irritability 
subscale score.
The incidences of adverse events in placebo and ari-
piprazole groups were 73.3 and 83.0%, respectively. All 
patients in aripiprazole group completed the study, and no 
serious adverse events were reported. Three patients in pla-
cebo group discontinued because of adverse events (n = 1) 
and other reasons (n = 2).
Aripiprazole produced a significant improvement in the 
mean ABC-J irritability subscale score relative to placebo 
from week 3 through week 8. The most common adverse 
event in the aripiprazole group was somnolence (51.1%), 
but this is usually a tolerable AE for patients.
Aripiprazole was effective and generally safe and well-
tolerated in the treatment of irritability associated with 
ASD in Japanese children and adolescents.
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